62933-57-7

Usage

Uses

Used in Pharmaceutical Industry:
1',2'-O-diacetyl-L-biopterin is used as a cofactor in the synthesis of neurotransmitters for the treatment of various neurological and psychiatric disorders. Its role in the production of neurotransmitters like catecholamines, serotonin, and nitric oxide makes it a valuable component in the development of medications targeting these pathways.
Used in Research Applications:
1',2'-O-diacetyl-L-biopterin is used as a research tool to study the function and regulation of enzymes involved in neurotransmitter synthesis. It helps researchers understand the mechanisms underlying various neurological and psychiatric conditions and develop potential therapeutic strategies.
Used in Diagnostic Applications:
1',2'-O-diacetyl-L-biopterin can be used as a diagnostic marker to assess the levels of neurotransmitters and enzyme activities in patients. This information can be valuable in diagnosing and monitoring the progression of neurological and psychiatric disorders.
Used in Pain Management:
1',2'-O-diacetyl-L-biopterin is used to increase BH4 levels, which in turn boosts sensitivity to pain. This property can be utilized in the development of pain management therapies and interventions.

Upstream product

• 1126386-90-0 C₁₁H₁₆O₇ 
• 123168-30-9 5-deoxy-L-ribose phenylhydrazone 
• 93978-94-0 5-deoxy-L-ribose 
• 4159-66-4 (R)-1-((4R,5S)-5-((S)-1-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)ethane-1,2-diol 
• 35011-47-3 2,4,5-triamino-6-hydroxypyrimidine sulfate 
• 13039-80-0 5-deoxy-L-(+)-arabinose-diethylmercaptal 
• 5328-37-0 L-arabinose 
• 95895-36-6 5-deoxy-2,3,4-O-triacetyl-L-arabinose-phenylhydrazone 
• 13039-79-7 5-tosyl-L-(+)-arabinose-diethylmercaptal 
• 43179-48-2 L-arabinose di(ethylthio)acetal 
• 13039-56-0 5-deoxy-L-arabinose 
• 35011-47-3 2,4,5-triaminopyrimidin-6(1H)-one sulfate monohydrate 
• 1004-75-7 2,5,6-triamino-4-hydroxypyrimidine 
• 32363-64-7 2-N-Acetyl-1',2'-di-O-acetylbiopterin 

Downstream Products

• 22150-76-1 L-erythro biopterin 
• 81827-31-8 2-N-acetyl-1',2'-di-O-acetyl-L-erythro-biopterin 
• 22150-76-1 biopterin 

Relevant academic research and scientific papers

Preparation method of sapropterin dihydrochloride

The invention relates to a preparation method of sapropterin dihydrochloride shown as formula (I) as shown in the specification. The preparation method comprises the steps of taking 5-deoxy arabinoseas a raw material, performing acetylation reaction in the presence of acetic anhydride to form an intermediate DL-1, allowing DL-1 to react with phenylhydrazine under the catalysis of acetic acid to form an intermediate DL-2, allowing DL-2 and pyrimidylamine sulfate to give a ring closing reaction under the catalysis of anhydrous lithium perchlorate to form an intermediate DL-3, directly oxidizingDL-3 through elemental iodine without purification to form an intermediate DL-4, hydrolyzing DL-4 through potassium hydroxide to form L-biopterin (DL-5), and reducing and salifying L-biopterin through a platinum catalyst to form sapropterin dihydrochloride. The preparation method is easy and simple to operate, high in yield, low in energy consumption and suitable for industrial production, the total yield of the preparation method is greater than 70%, and the purity of a final product reaches above 99.5%.

NOVEL PROCESS FOR THE PREPARATION OF SAPROPTERIN DIHYDROCHLORIDE AND ITS KEY INTERMEDIATE, L-BIOPTERIN

The present invention relates to a novel process for the preparation of Sapropterin dihydrochloride of formula (1) and its key intermediate L-erythro-biopterin of formula (2). The present process is a simple and economically viable process for commercial production of Sapropterin dihydrochloride of formula (1) and its key intermediate L-biopterin of formula (2).

COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES

The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III; and methods for treating or preventing metabolic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of phenylketonuria, cardiovascular disease, autism, ADHD, hypertension, endothelial dysfunction and chronic kidney disease.

Method for producing L-biopterin

To provide a method for producing L-biopterin on a large industrial scale by using a reagent which is inexpensive and easy to handle, without requiring a use of any particular equipment or plants.

169. Pterinechemistry Part 84 A New, Regiospecific Synthesis of L-Biopterin

Pure L-biopterin was obtained in 42percent yield by the condensation of 5-deoxy-L-arabinose-phenylhydrazone-triacetate with 4-hydroxy-2,5,6-triaminopyrimidine, followed by iodine oxidation of the formed tetrahydropterin derivative to 1',2'-O-diacetyl-L-biopterin.Deacetylation was carried out with NH4OH.

Pteridines, LXXV. - Synthesis and Properties of Biopterin and Biopterin Analogs

The synthesis of biopterin (6), its 2-N,N-dimethyl- (8) and 4-thioxo derivative (19) as well as biolumazine (7) is described.The side chain of biopterin can be modified by reaction of α-acetoxy-isobutyryl chloride to yield 6-(L-threo-2-acetoxy-1-chloropropyl)pterin (10), which can be used as a starting material for further derivatisations. 2,1',2'-Triacylbiopterins (14, 16) possess a hydrolytically labile N-acyl group.The newly synthesized compounds were characterized by pK-determinations, UV, and NMR spectra.